Consensus NextCure, Inc.

Stocks

NXTC

US65343E2072

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 31/10/2026 am IST			5-day change	1st Jan Change
6.310 ^USD	-3.30%		+26.71%	-55.53%

04/09	NextCure Enters Into Ninth Amendment To Lease Agreement And Vacates Premises At 8000 Virginia Manor Road	CI
12/08	RTW Biotech's Avere to go public in US in reverse merger with NextCure	AN

Evolution of the Average Target: NextCure, Inc.

Evolution of the Average Target - NextCure, Inc.

Evolution of the Target Price: NextCure, Inc.

Evolution of the Target Price - NextCure, Inc.

Changes in Analyst Recommendations: NextCure, Inc.

e77005.pSrrjlgQkAvln_4UimgnMdUnolLoiO-2lkvHQBMcFD8.lGu0_zNW9WOp07BexV1uAeZx5mS8sNiFwBywCSVlLQrIbLrCMkj2bYvrmQ~2b10dd13e53dcedfb24768a771d996ee

Analysts' recommendations: NextCure, Inc.

08/23/08	HC Wainwright Initiates NextCure With Buy Rating, $7 Price Target	MT
04/22/04	BTIG Lowers NextCure's Price Target to $8 From $27, Maintains Buy Rating	MT
04/22/04	Needham Lowers NextCure's Price Target to $6 From $12, Maintains Buy Rating	MT
04/22/04	Roth Capital Lowers NextCure's Price Target to $4 From $6, Maintains Neutral Rating	MT
04/22/04	Ladenburg Downgrades NextCure to Neutral From Buy	MT
04/22/04	Piper Sandler Adjusts Price Target on NextCure to $6 From $13, Maintains Overweight Rating	MT
23/22/23	Truist Securities Adjusts NextCure's Price Target to $15 From $19, Reiterates Buy Rating	MT
23/22/23	Piper Sandler Lowers NextCure's Price Target to $13 From $21, Maintains Overweight Rating	MT
01/22/01	Ladenburg Thalmann Initiates NextCure at Buy With $16 Price Target	MT
05/21/05	Needham Adjusts Price Target on NextCure to $14 from $30, Keeps Buy Rating	MT
09/21/09	NextCure : Piper Sandler Adjusts NextCure's Price Target to $21 From $26, Maintains Overweight Rating	MT
05/21/05	NextCure : Truist Securities Upgrades NextCure to Buy From Hold; Price Target is $19	MT
15/21/15	NextCure : BofA Securities Downgrades NextCure to Underperform From Neutral, Adjusts Price Target to $10 From $13	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	NEXTCURE, INC.			-	-	+216.96%
	WUXI APPTEC CO., LTD.					+42.48%
	ARGENX SE					+24.46%
	LONZA GROUP AG					+8.41%
	IQVIA HOLDINGS INC.					+15.87%
	BEONE MEDICINES AG					+17.86%
	REVOLUTION MEDICINES, INC.					+35.3%
	GENMAB A/S					+1.94%
	CELLTRION, INC.					+41.27%
	INSMED INCORPORATED					+72.28%
	Average					+47.68%
	Weighted average by Cap.					+27.03%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

6.310USD

Average target price

20.00USD

Spread / Average Target

+216.96%

High Price Target

20.00USD

Spread / Highest target

+216.96%

Low Price Target

20.00USD

Spread / Lowest Target

+216.96%

Analyst Consensus Detail

Analyst consensus - NextCure, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - NextCure, Inc.

Stock Market
Stocks
NXTC Stock
Consensus NextCure, Inc.

As early as today, start finding the best investment opportunities!